Drug facts
MoleculeAbiraterone (Zytiga)
Generics already compete: 12 makers on the market. 19 A-rated products from 12 makers substitute at the counter.
Zytiga was first approved by the FDA on 04/28/2011 under NDA 202379; the application holder is Janssen Biotech Inc.
The latest NADAC for ABIRATERONE ACETATE 250 MG TAB is $0.79 per unit (as of 10/28/2026).
Holder Janssen Biotech IncApplication NDA 202379Approved 04/28/2011
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Zytiga patent listed in the Orange Book Orange Book
- Later patents, other products
- Yonsa 05/20/2034 Orange Book
02Competition
- Generics
- 12 generic makers Orange Book
- First generic approved
- 10/31/2018 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Abiraterone profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.79 per unitABIRATERONE ACETATE 250 MG TAB, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Janssen Biotech Inc Orange Book
- Application
- NDA 202379 Orange Book
- First approved
- 04/28/2011 Orange Book
- Dosage forms
- tablet
- Routes
- oral
- Other brand names
- Yonsa
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.